公开(公告)号：US11993570B2

公开(公告)日：2024-05-28

申请号：US17900412

申请日：2022-08-31

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Satoru Matsumoto ,  Yoshimasa Omori ,  Masahiro Mineno ,  Yasutaka Hoashi

IPC: C07C229/12 ,  A61K9/16 ,  C07C69/533 ,  C12N15/113

CPC classification number: C07C69/533 ,  A61K9/1617 ,  C12N15/113

Abstract: The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.

公开(公告)号：US20230257338A1

公开(公告)日：2023-08-17

申请号：US17900412

申请日：2022-08-31

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Satoru Matsumoto ,  Yoshimasa Omori ,  Masahiro Mineno ,  Yasutaka Hoashi

IPC: C07C69/533 ,  A61K9/16 ,  C12N15/113

CPC classification number: C07C69/533 ,  A61K9/1617 ,  C12N15/113

Abstract: The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.

公开(公告)号：US20220098142A1

公开(公告)日：2022-03-31

申请号：US17267179

申请日：2019-08-08

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoru Matsumoto ,  Yoshimasa Omori ,  Masahiro Mineno ,  Yasuhiro Sawai ,  Nozomu Kakimoto ,  Yusutaka Hoashi

IPC: C07C229/12 ,  C12N15/113 ,  A61K9/51

Abstract: The present invention provides a technique capable of transferring an active ingredient, particularly, a nucleic acid, to a cell with excellent efficiency and a cationic lipid for use in this technique, etc. The cationic lipid of the present invention is a compound represented by the formula (I) or a salt thereof. n1 represents an integer of 2 to 6, n2 represents an integer of 0 to 2, n3 represents an integer of 0 to 2, L represents —C(O)O— or —NHC(O)O—, Ra represents a linear C5-13 alkyl group, a linear C13-17 alkenyl group or a linear C17 alkadienyl group, Rb represents a linear C2-9 alkyl group, Rc represents a hydrogen atom or a linear C2-9 alkyl group, Rd represents a hydrogen atom or a linear C2-9 alkyl group, Re represents a linear C2-9 alkyl group, and Rf represents a linear C2-9 alkyl group.

公开(公告)号：US20200331841A1

公开(公告)日：2020-10-22

申请号：US16958244

申请日：2018-12-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoru Matsumoto ,  Yoshimasa Omori ,  Masahiro Mineno ,  Yusutaka Hoashi

IPC: C07C69/533 ,  C12N15/113 ,  A61K9/16

Abstract: The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.